Why Genfit Is Cratering Today
Genfit (NASDAQ: GNFT), a late-stage biopharmaceutical company, reported some disappointing news on Monday regarding one of its leading pipeline candidates, Elafibranor. As a result, the company's stock is falling off a cliff today. Genfit's shares are down by 65.2% as of 12:46 p.m. EDT on Tuesday.
Elafibranor is an investigational treatment for a liver disease called Nonalcoholic steatohepatitis, or NASH for short. Interim analysis of RESOLVE-IT -- a phase 3 clinical trial evaluating Elafibranor in NASH patients -- showed that the treatment failed to achieve statistically significant NASH resolution without worsening of fibrosis (scarring in the lungs) at week 72, which was the primary endpoint of the study.
Image Source: Getty Images.
Source Fool.com
